( July 21, 2026, 1:42 PM EDT) -- WASHINGTON, D.C. — A pharmaceutical company’s filing of a petition with the District of Columbia Circuit U.S. Court of Appeals to review the U.S. Food and Drug Administration’s denial of a new drug application (NDA) deprived the district court of jurisdiction to hear the company’s argument that the FDA erred or to consider whether the employee who made the decision was improperly appointed, a federal judge in the District of Columbia held....